MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases
- Publication Type:
- Journal Article
- Citation:
- Drug Delivery and Translational Research, 2017, 7 (1), pp. 168 - 178
- Issue Date:
- 2017-02-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
| 10.1007%2Fs13346-016-0343-6.pdf | Published Version | 1.03 MB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
© 2016, Controlled Release Society. The rapid advancement in the area of microRNAs (miRNAs) from discovery to their translation into therapeutic moieties reflects their significance as important regulators in the management of disease pathology. The miRNAs can potentially be a new class of drugs in the near future for the treatment of various lung diseases, but it lacks the current knowledge how these identified therapeutic moieties can be designed into an effective, patient complaint and targeted drug delivery system. miRNAs have characteristic features like small size and low molecular weight which makes them easily translated into an effective drug delivery system. In this review, we have summarised the concept of miRNAs and different approaches which can be employed to deliver miRNAs effectively and safely to the target cells including the challenges associated with their development in particular emphasis on pulmonary diseases. Such approaches will be of interest for both the biological and formulation scientists to understand and explore the new vistas in the area of miRNA delivery for pulmonary inflammatory diseases.
Please use this identifier to cite or link to this item: